04-2395. Reporting of Pregnancy Success Rates From Assisted Reproductive Technology Programs  

  • Start Preamble

    AGENCY:

    Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

    ACTION:

    Notice.

    SUMMARY:

    The CDC is tasked with implementing the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA), Public Law 102-493. As mandated by this law CDC publishes annual reports of pregnancy success rates from ART clinics and embryo laboratory certification status of these clinics. Section 2(a) of Public Law 102-493 (42 U.S.C. 263a -1) requires that each assisted reproductive technology (ART) program shall annually report to the Secretary, through the Centers for Disease Control and Prevention, (a) pregnancy success rates achieved by such ART programs, and (b) the identity of each embryo laboratory used by such ART programs, and whether the laboratory is certified or has applied for such certification under this act. Section (6) states that the Secretary, through the CDC, shall annually publish and distribute to the States and the public, pregnancy success rates reported to the Secretary under section 2(a)(1) and, in the case of an assisted reproductive technology program which failed to report one or more success rates as required under each section, the name of each such program and each pregnancy success rate which the program failed to report.

    CDC first implemented the FCSRCA in 1997, and has obtained and published data for ART procedures performed in 1995, 1996, 1997, 1998, 1999 and 2000. Currently, CDC has a contract with the Society for Assisted Reproductive Technology (SART) to annually obtain a copy of their clinic-specific database. The existing contract will be used to obtain and publish data for ART procedures performed in 2001, 2002 and 2003. Details on the current process are outlined in the September 1, 2000 Federal Register notice (Volume 65, No. 171, pages 53310-53316).

    CDC is currently in the process of selecting a contractor for the 2004, 2005, 2006, 2007, and 2008 data reporting years. We anticipate awarding the contract in February, 2004. Based on that timeframe, we anticipate that the data collection system for 2004 data reporting will be available to clinics in summer, 2004. The new contract to be awarded will cover clinic tracking, data collection and quality assurance and validation processes for ART procedures performed in 2004, 2005, 2006, 2007 and 2008. The data collection process is expected to be similar to the current data collection process (see September 1, 2000 Federal Register notice, Volume 65, No. 171, pages 53310-53316).

    Under the new contract, the contractor shall furnish all personnel, facilities, equipment, supplies, and materials necessary to assist CDC to produce and publish an annual report of pregnancy success rates and embryo laboratory certification status, as Start Printed Page 5549mandated by the Fertility Clinic Success Rate and Certification Act of 1992. (FCSRCA), Public Law 102-493. The Contractor shall meet the following requirements:

    a. The contractor shall track all clinics performing ART in the United States and its territories that are known to be in operation for each reporting year and track all clinic reorganizations and closings.

    b. The contractor shall develop a standardized data collection system, subject to Office of Management and Budget (OMB) requirements, that appropriately collects all specified data from clinics.

    c. The contractor shall implement a quality assurance system each year to ensure that the data delivered to CDC are of acceptable quality and completeness.

    d. The contractor shall distribute the data collection software, along with instructions, to all clinics by preset deadlines.

    e. The contractor shall provide ongoing technical assistance to each site as needed by developing, implementing, and maintaining a Web site and telephone help line for technical assistance in all data collection issues.

    f. The contractor shall deliver to the CDC, preliminary and final clinic and cycle specific data for each reporting year. The contractor shall deliver all necessary documentation pertaining to the annual data sets.

    g. The contractor shall provide: (1) A listing of all assisted reproductive technology clinics that are included in the clinic and cycle specific datasets each reporting year; and, (2) a listing of all assisted reproductive technology clinics that were performing assisted reproductive technology cycles and were thus required to report data under FCSRCA, but failed to report such data to the contractor. The lists of reporting and non-reporting clinics shall include all clinics known to be in operation during a given reporting year.

    h. Each year, the contractor shall prepare and describe a data validation quality assurance plan in conjunction with the CDC. The contractor shall perform data validation site visits, enter the data collected during these visits into an electronic data system, and provide both the electronic datafile and a hard copy of all abstraction forms to the CDC.

    The amount and type of data collected will be similar to the current system requirements and will include clinic information, patient demographic information, patient history, ART cycle information, and ART outcome information. A detailed listing of current data elements and definitions for data to be collected are outlined in the Federal Register notice (see September 1, 2000 Federal Register notice, Volume 65, No. 171, pages 53310-53316).

    The current database system is based on Microsoft Access. In this new contract, CDC will require that the contractor develop a new database system. The database system developed under this new contract must have the capability to record data for every treatment cycle of ART initiated, convert collected data to a database such as Microsoft Access (and ultimately the database must be converted into SAS System Version 8.0 or later). CDC will also require that the database developed include all programming necessary to take the data entered for each ART cycle initiated and compute all statistics needed for presentation in the report. The contractor will submit two datasets to CDC—one organized such that each ART cycle initiated is a unique observation, and one organized such that summary statistics by each clinic is a unique observation.

    Each ART program should be aware that the Paperwork Reduction Act is applicable to this data collection. Under the Paperwork Reduction Act of 1995, a Federal agency shall not conduct or sponsor a collection of information from ten or more persons other than Federal employees, unless the agency has submitted a Standard Form 83, Clearance Request, to the Director of the Office of Management and Budget (OMB), and OMB has approved the collection of information. A person is not required to respond to a collection of information unless it displays a currently valid OMB control number. CDC has obtained OMB approval to collect this data under OMB control No. 0920-0556.

    Currently, each ART program must use the required database system (developed by SART) to enter and submit data. Under the new contract, CDC will continue to require a single data collection system (to be developed by the contractor). In addition, each ART program currently submits its dataset output from the required software to the contractor at a central site. The contractor then compiles all the datasets from specific sites into a single dataset. That requirement will continue.

    Currently, all ART programs reporting their data are subject to an annual external validation of their data collection and reporting activities by appropriately trained professionals from outside the clinic staff. This review includes but is not limited to examination of medical and laboratory records and comparison of data in the reporting database with the data in the medical record. External validation will continue with the new contract.

    Every clinic will maintain a copy of all information included in the reporting database and must be able to link each patient, cycle and oocyte retrieved from the reporting database to the appropriate medical and laboratory records for external validation activities. The new contractor will provide the necessary personnel to perform the validation visits.

    ART success rates will be similar to those currently presented in the annual reports and will be defined and characterized as described below:

    Success rates for fresh, nondonor cycles will be defined as—

    1. The rate of pregnancy after completion of ART according to the number of:

    • All ovarian stimulation or monitoring procedures.

    2. The rate of live birth after completion of ART according to the number of:

    a. All ovarian stimulation or monitoring procedures.

    b. Oocytes retrieval process.

    c. Embryo (or Zygote, or oocyte) transfer procedures.

    3. The rate of singleton live birth after completion of ART according to the number of:

    a. All ovarian stimulation or monitoring procedures.

    b. Embryo (or zygote, or oocyte) transfer procedures.

    Success rates for cycles using thawed embryos and cycles using donor oocytes or embryos will be defined as—

    4. The rate of live birth after completion of ART according to the number of:

    • Embryo (or zygote, or oocyte) transfer procedures.

    5. The rate of singleton live birth after completion of ART according to the number of:

    • Embryo (or zygote, or oocyte) transfer procedures.

    Reporting requirements, data elements, definitions, and success rates will be periodically reviewed and updated as new knowledge concerning ART methods and techniques becomes available.

    Until a new contract has been awarded, ART programs are advised to refrain from entering 2004 data into the current data collection system. CDC will continue to provide information to all Start Printed Page 5550ART programs regarding the status of the new contract and future years' data collection activities as information becomes available.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Victoria Wright, Assisted Reproductive Technology Epidemiology Unit at (770) 488-6370.

    Start Signature

    Dated: January 29, 2004.

    Joseph R. Carter,

    Deputy Chief Operating Officer, Centers for Disease Control and Prevention.

    End Signature End Further Info End Preamble

    [FR Doc. 04-2395 Filed 2-4-04; 8:45 am]

    BILLING CODE 4163-18-P

Document Information

Published:
02/05/2004
Department:
Centers for Disease Control and Prevention
Entry Type:
Notice
Action:
Notice.
Document Number:
04-2395
Pages:
5548-5550 (3 pages)
PDF File:
04-2395.pdf